Published in Arch Biochem Biophys on January 01, 2000
The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol (2013) 5.57
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med (2003) 3.13
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A (2006) 2.73
Chemical combination effects predict connectivity in biological systems. Mol Syst Biol (2007) 2.42
Development of bisphosphonates. Breast Cancer Res (2001) 1.63
Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts. J Oral Maxillofac Surg (2011) 1.50
The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol (2005) 1.49
Targeting isoprenoid biosynthesis for drug discovery: bench to bedside. Acc Chem Res (2010) 1.40
Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer (2006) 1.22
Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women. Eur J Epidemiol (2004) 1.20
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer (2003) 1.10
The acidocalcisome as a target for chemotherapeutic agents in protozoan parasites. Curr Pharm Des (2008) 1.05
Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase. Curr Med Chem (2011) 1.03
Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells. Leuk Res (2010) 1.03
Vacuolar proton pyrophosphatase activity and pyrophosphate (PPi) in Toxoplasma gondii as possible chemotherapeutic targets. Biochem J (2000) 1.02
Capsaicin-sensitive sensory nerve fibers contribute to the generation and maintenance of skeletal fracture pain. Neuroscience (2009) 1.00
The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone (2009) 0.99
The mevalonate pathway in C. elegans. Lipids Health Dis (2011) 0.98
The Interleukin-6 inflammation pathway from cholesterol to aging--role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. Immun Ageing (2007) 0.94
The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer (2002) 0.92
Mammalian hibernation as a model of disuse osteoporosis: the effects of physical inactivity on bone metabolism, structure, and strength. Am J Physiol Regul Integr Comp Physiol (2008) 0.88
Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Leuk Res (2009) 0.87
Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate. Eukaryot Cell (2006) 0.86
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats. J Orthop Surg Res (2011) 0.85
Competition between isoprene emission and pigment synthesis during leaf development in aspen. Plant Cell Environ (2013) 0.84
Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion. J Biol Chem (2012) 0.84
Alendronate inhibits VEGF expression in growth plate chondrocytes by acting on the mevalonate pathway. Open Orthop J (2009) 0.84
Drugs in development: bisphosphonates and metalloproteinase inhibitors. Arthritis Res Ther (2002) 0.83
Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells. Br J Cancer (2004) 0.82
Small interfering RNA knocks down the molecular target of alendronate, farnesyl pyrophosphate synthase, in osteoclast and osteoblast cultures. Mol Pharm (2011) 0.82
The susceptive alendronate-treatment timing and dosage for osteogenesis enhancement in human bone marrow-derived stem cells. PLoS One (2014) 0.81
Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women. Yonsei Med J (2010) 0.81
A novel EST-derived RNAi screen reveals a critical role for farnesyl diphosphate synthase in β2-adrenergic receptor internalization and down-regulation. FASEB J (2012) 0.81
Bisphosphonate inhibitors reveal a large elasticity of plastidic isoprenoid synthesis pathway in isoprene-emitting hybrid aspen. Plant Physiol (2015) 0.80
Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. BMC Cancer (2007) 0.80
Pyridines and pyrimidines mediating activity against an efflux-negative strain of Candida albicans through putative inhibition of lanosterol demethylase. Antimicrob Agents Chemother (2004) 0.80
Suppression of CYP2B induction by alendronate-mediated farnesyl diphosphate synthase inhibition in primary cultured rat hepatocytes. Drug Metab Dispos (2008) 0.80
Bisphosphonates inhibit expression of p63 by oral keratinocytes. J Dent Res (2011) 0.79
Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries. ACS Med Chem Lett (2015) 0.78
Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res (2005) 0.78
S-carvone suppresses cellulase-induced capsidiol production in Nicotiana tabacum by interfering with protein isoprenylation. Plant Physiol (2013) 0.78
Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women. Maturitas (2007) 0.77
Farnesyl diphosphate synthase, the target for nitrogen-containing bisphosphonate drugs, is a peroxisomal enzyme in the model system Dictyostelium discoideum. Biochem J (2012) 0.76
Targeting Cancer Cells with a Bisphosphonate Prodrug. ChemMedChem (2016) 0.75
Olefin Isomers of a Triazole Bisphosphonate Synergistically Inhibit Geranylgeranyl Diphosphate Synthase. Mol Pharmacol (2017) 0.75
Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis. Clin Exp Metastasis (2015) 0.75
Hydrogen Sulfide and Carbon Monoxide Protect Gastric Mucosa Compromised by Mild Stress Against Alendronate Injury. Dig Dis Sci (2016) 0.75
Bisphosphonates and atypical subtrochanteric fractures of the femur. Bone Joint Res (2017) 0.75
Clodronate acts on human osteoclastic cell proliferation, differentiation and function in a bioreversible manner. Clin Cases Miner Bone Metab (2007) 0.75
Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders. Clin Cases Miner Bone Metab (2007) 0.75
[Are statins of value in therapy of osteoporosis?]. Wien Med Wochenschr (2003) 0.75
Bisphosphonate inhibits the expression of cyclin A2 at the transcriptional level in normal human oral keratinocytes. Int J Mol Med (2017) 0.75
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A (1999) 2.66
Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci U S A (1993) 1.89
M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ (2003) 1.83
Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins. Cell Death Differ (2004) 1.44
Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem (1999) 1.38
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone (2001) 1.32
Mutations in the cytoplasmic domain of the integrin beta1 chain indicate a role for endocytosis factors in bacterial internalization. J Biol Chem (1996) 1.26
Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem Biophys Res Commun (1989) 1.22
Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone (2008) 1.19
In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology (2000) 1.14
Cloning, analysis, and bacterial expression of human farnesyl pyrophosphate synthetase and its regulation in Hep G2 cells. Biochemistry (1989) 1.04
Cytochemical localization of adenylate cyclase and of calcium ion, magnesium ion-activated ATPases in the dense tubular system of human blood platelets. Biochim Biophys Acta (1978) 0.98
The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone (2011) 0.97
Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Curr Med Res Opin (2005) 0.97
The determination of the rate of deiodination of thyroxine in human subjects. J Clin Invest (1965) 0.96
Cross-hybridization and relationships of various papillomavirus DNAs at different degrees of stringency. Intervirology (1987) 0.90
Mineralization of cancellous bone after alendronate and sodium fluoride treatment: a quantitative backscattered electron imaging study on minipig ribs. Bone (1997) 0.89
Chimeric integrins expressed in retinal ganglion cells impair process outgrowth in vivo. Mol Cell Neurosci (1995) 0.88
Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. Endocrinology (1999) 0.88
Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. Biochim Biophys Acta (1998) 0.87
Structure of the starburst amacrine network in the cat retina and its association with alpha ganglion cells. J Comp Neurol (1989) 0.86
Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res (1992) 0.85
KT5720 and U-98017 inhibit MAPK and alter the cytoskeleton and cell morphology. J Cell Physiol (1998) 0.82
Effects of sodium fluoride and alendronate on the bone mineral in minipigs: a small-angle X-ray scattering and backscattered electron imaging study. J Bone Miner Res (1996) 0.81
Formation of calcifying matrix by osteosarcoma cells in diffusion chambers in vivo. Calcif Tissue Int (1986) 0.80
Histomorphometric evidence for echistatin inhibition of bone resorption in mice with secondary hyperparathyroidism. Endocrinology (1998) 0.77
An oral papillomavirus that infected one coyote and three dogs. Vet Pathol (1991) 0.75
Discussion: Newer bisphosphonates in the treatment of Paget's disease of bone: where we are and where we want to go. J Bone Miner Res (1999) 0.75
[Treatment of chondrosarcomas of the extremities with isolated perfusion of radioactive S35]. Minerva Med (1967) 0.75